Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Nativis to Present at the Ladenburg Thalmann 2016 Healthcare Conference

Posted on: 15 Sep 16

Nativis, Inc., a clinical stage life science bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that it will be featured as a presenting company at the Ladenburg Thalmann 2016 Healthcare Conference, being held on September 27, 2016 at The Sofitel Hotel in New York City.

Chris Rivera, Nativis’ President and Chief Executive Officer, will provide a business overview and update on the Company's strategy during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Details for the presentation are as follows:

Date: Monday, September 27, 2016
Time: 3:00 – 3:25pm ET
Room: Madeleine – Track 6

About Nativis, Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.

View source version on

Business Wire

Last updated on: 15/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.